Detlev Ganten
Chairman at Charité - Universitätsmedizin Berlin
Profile
Detlev Ganten is currently the Chairman at Charité - Universitätsmedizin Berlin and Max Planck Institute of Colloids & Interfaces.
He is also the Chairman at Max Planck Institute of Molecular Plant Physiology, and a Member-Supervisory Board at Eckert & Ziegler AG and GlycoUniverse GmbH & Co KGaA.
Additionally, he is the President of World Health Summit.
In the past, he served as the Director of Max-Delbrück-Centrum für Molekulare Medizin (MDC) and was a Member-Supervisory Board at Eckert & Ziegler Strahlen- und Medizintechnik AG.
He was also a Member-Administrative Board at Université PSL.
He received his doctorate from McGill University and his undergraduate degree from Eberhard Karls Universität Tübingen.
Detlev Ganten active positions
| Companies | Position | Start |
|---|---|---|
| Charité - Universitätsmedizin Berlin | Chairman | 31/12/2004 |
| Max Planck Institute of Colloids & Interfaces | Chairman | 31/12/2009 |
| GlycoUniverse GmbH & Co KGaA | Director/Board Member | - |
Eckert & Ziegler AG
 Eckert & Ziegler AG Hospital/Nursing ManagementHealth Services Eckert & Ziegler AG is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The private company has a global presence of subsidiaries in several regions and is based in Berlin, DE. With nearly 1,000 employees, the German company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. The CEO of the company is Andreas Eckert. | Director/Board Member | - |
| World Health Summit | President | 31/12/2008 |
| Max Planck Institute of Molecular Plant Physiology | Chairman | - |
Former positions of Detlev Ganten
| Companies | Position | End |
|---|---|---|
| ECKERT & ZIEGLER SE | Director/Board Member | 28/05/2019 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | Director/Board Member | 31/12/2003 |
| Université PSL | Director/Board Member | - |
Training of Detlev Ganten
| McGill University | Doctorate Degree |
| Eberhard Karls Universität Tübingen | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ECKERT & ZIEGLER SE | Health Technology |
| Private companies | 5 |
|---|---|
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | Commercial Services |
Eckert & Ziegler AG
Eckert & Ziegler AG Hospital/Nursing ManagementHealth Services Eckert & Ziegler AG is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The private company has a global presence of subsidiaries in several regions and is based in Berlin, DE. With nearly 1,000 employees, the German company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. The CEO of the company is Andreas Eckert. | Health Services |
| GlycoUniverse GmbH & Co KGaA | |
| World Health Summit | |
| Max Planck Institute of Molecular Plant Physiology |
- Stock Market
- Insiders
- Detlev Ganten
